WA
BIIB icon

Winfield Associates’s Biogen BIIB Stock Holding History

Winfield Associates’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-87
Closed -$28K – 176
2017
Q4 		$28K Sell
87
-196
-69% -$62.9K 0.01% 254
2017
Q3 		$89K Sell
283
-92
-25% -$27.2K 0.05% 152
2017
Q2 		$102K Sell
375
-92
-20% -$24.3K 0.06% 148
2017
Q1 		$128K Buy
467
+67
+17% +$18.9K 0.07% 137
2016
Q4 		$113K Sell
400
-40
-9% -$11.9K 0.07% 139
2016
Q3 		$138K Buy
440
+40
+10% +$11.8K 0.09% 126
2016
Q2 		$97K Sell
400
-20
-5% -$5.27K 0.06% 140
2016
Q1 		$109K Buy
420
+20
+5% +$5.28K 0.07% 128
2015
Q4 		$123K Hold
400
– – 0.08% 126
2015
Q3 		$117K Sell
400
-100
-20% -$33K 0.09% 124
2015
Q2 		$202K Buy
500
+200
+67% +$80.3K 0.14% 109
2015
Q1 		$127K Buy
300
+200
+200% +$78.8K 0.09% 128
2014
Q4 		$34K Hold
100
– – 0.03% 178
2014
Q3 		$33K Hold
100
– – 0.02% 179
2014
Q2 		$31K Sell
100
-50
-33% -$15K 0.02% 190
2014
Q1 		$46K Buy
+150
New +$47.6K 0.04% 162

Other funds holding BIIB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Winfield Associates's BIIB Position: Q1 2018 in Review

Winfield Associates sold out of Biogen (BIIB) in Q1 2018, closing a stake of 87 shares — an estimated $28K sold.

Winfield Associates first reported a position in BIIB in Q1 2014 and held it in 16 quarters. The position peaked at $202K in Q2 2015. 1,103 funds tracked by Wall St. Rank hold BIIB as of Q1 2018.

  • Winfield Associates reported no remaining Biogen position as of Q1 2018 after selling out during the quarter.
  • Winfield Associates sold 87 Biogen shares in Q1 2018, an estimated $28K.
  • Winfield Associates first reported a position in Biogen in Q1 2014 and held it in 16 quarters.
  • Winfield Associates's Biogen position peaked at $202K in Q2 2015.
  • 1,103 funds tracked by Wall St. Rank held Biogen as of Q1 2018.

Based on Winfield Associates's 13F filing for Q1 2018, filed 10 May 2018.